Bluefish Pharmaceuticals
Mariam Motamen has extensive experience in regulatory affairs and project management across various pharmaceutical companies, currently serving as Manager of Regulatory Affairs & Quality Assurance at Bluefish Pharmaceuticals since November 2020. Previous roles include Regulatory Affairs Manager at DREHM Pharma GmbH and Regulatory Affairs Executive for Austria, Germany, and Switzerland at Norgine, where responsibilities encompassed lifecycle management and the preparation of regulatory submissions. Prior to that, Mariam held positions in project management at Baxter International Inc. and technical support at Novartis. Through a strong educational background, including a Master's degree in Drug Regulatory Affairs from The University of Bonn and a Project Management Professional (PMP) certification, Mariam has developed a robust skill set in regulatory strategy, compliance, and cross-functional project leadership.
This person is not in any offices
Bluefish Pharmaceuticals
Founded in Sweden, with its long tradition of industrial entrepreneurship, Bluefish Pharmaceuticals has become one of the most progressive generics pharmaceuticals companies. At Bluefish, we strive to make quality medicines accessible to more people. We create value in the full pharmaceutical value chain from developing to manufacturing and successfully marketing generic pharmaceuticals and we take pride in doing this in an innovative, responsible and cost-efficient way. Bluefish currently conducts operations in 19 countries in Europe and, over the next few years, will also expand outside Europe with the aim of becoming a global player. Our corporate culture and close collaboration with development and manufacturing partners are integral parts of our effort to deliver quality products at affordable prices. We offer a product portfolio consisting of a broad range of high quality generics for all major therapeutic areas. It is part of our long-term strategy to expand the product portfolio of off-patent blockbusters while at the same time offering a broader range of niche products within more narrow disease areas.